KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Recursion Pharmaceuticals (RXRX) Cost of Revenue (2022 - 2025)

Recursion Pharmaceuticals' Cost of Revenue history spans 4 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 11.58% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $71.0 million, up 56.84%, while the annual FY2025 figure was $71.0 million, 56.84% up from the prior year.
  • Cost of Revenue reached $14.3 million in Q4 2025 per RXRX's latest filing, down from $14.7 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $21.8 million in Q1 2025 to a low of $7.8 million in Q1 2022.
  • Average Cost of Revenue over 4 years is $12.9 million, with a median of $12.3 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: plummeted 34.05% in 2023, then surged 119.17% in 2025.
  • A 4-year view of Cost of Revenue shows it stood at $10.8 million in 2022, then decreased by 8.85% to $9.9 million in 2023, then increased by 29.48% to $12.8 million in 2024, then grew by 11.58% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Cost of Revenue are $14.3 million (Q4 2025), $14.7 million (Q3 2025), and $20.2 million (Q2 2025).